United States v. Norman Breedlove
756 F.3d 1036
7th Cir.2014Background
- Breedlove pleaded guilty to drug trafficking and firearms offenses and sought to leverage a plea deal for a lighter sentence.
- Before sentencing, Breedlove was found incompetent and committed to a federal facility for evaluation.
- The government sought involuntary antipsychotic medication under Sell v. United States to restore Competency for sentencing.
- Sell requires four factors: government interests, likelihood medication will restore competency, necessity/no viable alternatives, and medical appropriateness.
- District court held a Sell hearing, relied on two doctors’ testimony, and ordered involuntary Haloperidol treatment for up to four months.
- The district court also denied a reevaluation request, and Breedlove appealed the district court’s compliance with Sell and its individualized treatment plan.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether Breedlove’s crime is serious enough for Sell’s first factor. | Breedlove’s crimes are drug trafficking and gun possession. | The government must show crimes qualify as serious; Breedlove argues category applies only to violent offenses. | Crimes were serious given possible life sentence and broader societal impact. |
| Whether involuntary medication would significantly further the government’s interest. | Clear and convincing evidence shows medication will restore competency. | Reliance on a study with potential flaws undermines likelihood of restoration. | Courts may rely on expert testimony and corroborating studies; factor satisfied. |
| Whether there were viable alternatives to involuntary medication. | Non-medication treatments unlikely to restore competency given condition. | Less intrusive options could suffice; contentious point resolved against Breedlove. | Evidence supported no viable alternatives to restore competency. |
| Whether the treatment was medically appropriate. | Administration of Haloperidol aligns with medical standards to restore competency. | Concern about side effects and individual medical interests. | Treatment plan acceptable; risks monitored; medically appropriate under Sell. |
| Whether the district court provided an adequately individualized treatment plan and reexamination procedure. | Maximum dosage not stated; plan should specify dosage. | Detailed plan and length of treatment shown; not necessary to include explicit max dosage. | Plan sufficiently individualized; explicit maximum dosage not required given detail. |
Key Cases Cited
- Sell v. United States, 539 F.3d 166 (2003) (framework for involuntary antipsychotic medication to restore competency)
- United States v. Baldovinos, 434 F.3d 233 (2006) (assessing seriousness of crime for Sell factor)
- United States v. Hernandez-Vasquez, 513 F.3d 908 (2008) (non-categorical approach to Sell factor seriousness)
- United States v. Evans, 404 F.3d 227 (2005) (non-violent/non-property crimes may be considered under Sell)
- United States v. Green, 532 F.3d 538 (2008) (consideration of maximum statutory penalty to assess seriousness)
- Valenzuela-Puentes, 479 F.3d 1220 (2007) (Sell factor—seriousness of crime analysis)
- Debenedetto, 744 F.3d 465 (2013) (necessity and alternatives under Sell factor three)
- Chavez, 734 F.3d 1247 (2013) (reasoning on treatment plans under Sell)
- United States v. Lyons, 733 F.3d 777 (2013) (Sell factors reviewed de novo vs clear error)
- United States v. Tinnie, 629 F.3d 749 (2011) (Sell factors methodology in sentencing context)